Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $534,000 - $730,000
-200,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $520,000 - $842,000
200,000 New
200,000 $574,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $185M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Wolverine Asset Management LLC Portfolio

Follow Wolverine Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Asset Management LLC with notifications on news.